Karyopharm Therapeutics Files for Chapter 11 and Agrees to Merger
Karyopharm filed voluntary Chapter 11 petitions and entered a support agreement to merge with Ayrmid through a court-supervised sale. The company secured commitments for up to $55 million in debtor-in-possession financing; the transaction is expected to close in the first quarter of 2027, subject to court approval and other conditions.
Story updates
Karyopharm Therapeutics Inc. announced it has filed voluntary petitions for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the Southern District of Texas. As part of the restructuring, the company has entered into a support agreement to merge with Ayrmid Ltd.
through a court-supervised sale process. To support operations during the proceedings, Karyopharm has secured commitments for up to $55 million in debtor-in-possession (DIP) financing from its existing secured lenders. The transaction is expected to close in the first quarter of 2027, subject to court approval and other customary conditions.